| __timestamp | Travere Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 59644696 | 7461000 |
| Thursday, January 1, 2015 | 79541000 | 11960000 |
| Friday, January 1, 2016 | 98015000 | 13108000 |
| Sunday, January 1, 2017 | 103958000 | 17501000 |
| Monday, January 1, 2018 | 103654000 | 22472000 |
| Tuesday, January 1, 2019 | 128951000 | 24286000 |
| Wednesday, January 1, 2020 | 135799000 | 29689000 |
| Friday, January 1, 2021 | 149883000 | 38837000 |
| Saturday, January 1, 2022 | 220206000 | 47489000 |
| Sunday, January 1, 2023 | 265542000 | 53379000 |
Unleashing the power of data
In the competitive world of biotechnology, managing costs is crucial for success. Over the past decade, Travere Therapeutics, Inc. and Xencor, Inc. have demonstrated distinct strategies in handling their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Travere Therapeutics saw a staggering 345% increase in SG&A expenses, peaking at $265 million in 2023. This growth reflects their aggressive expansion and investment in operational capabilities. In contrast, Xencor, Inc. maintained a more conservative approach, with a 615% increase, reaching $53 million in the same period. This indicates a steady, controlled growth strategy. Understanding these trends provides valuable insights into how these companies balance innovation with financial prudence, offering lessons for emerging biotech firms aiming to thrive in a dynamic market.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.